Key result
Nitroglycerin improves hemodynamics and increases CGRP in CHF, especially in ALDH2*1/*1 homozygous patients.
Why the study?
The role of CGRP in nitroglycerin response and its association with ALDH2 Glu504Lys polymorphism in chronic heart failure patients was unclear.
Does the ALDH2 Glu504Lys polymorphism influence the hemodynamic and CGRP response to nitroglycerin in patients with chronic heart failure?
Does the ALDH2 Glu504Lys polymorphism influence the hemodynamic and CGRP response to nitroglycerin in patients with chronic heart failure?
p-value: p=<0.001
The ALDH2*2 polymorphism attenuates the hemodynamic response and CGRP release induced by nitroglycerin in patients with chronic heart failure.
ALDH2*2 may attenuate nitroglycerin response in CHF; hypothesis-generating and requires prospective validation before clinical use.
OBJECTIVE: The aim of this study was to investigate whether the neuropeptide calcitonin gene related peptide (CGRP) contributes to nitroglycerin (GTN) response in patients with chronic heart failure (CHF) and the association with the mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys (ALDH2*2) polymorphism. METHODS: This is a 2-period, placebo-controlled clinical study. An intravenous infusion of saline followed by GTN (20 μg/min), each for 2 hours, respectively, was given to 49 stable CHF patients. Blood pressure (BP), heart rate (HR) and respiratory rate (RR) were measured at baseline, at 10 min, 30 min, 1.0 h, 1.5 h, and 2.0 h after initiation of saline infusion and initiation of GTN therapy. Blood samples were drawn for the determination of plasma CGRP for 49 patients at baseline, and at 2.0 h after initiation of saline and GTN infusion, respectively. Global clinical status of the patients was evaluated. Left ventricular ejection (LVEF), left ventricular end-diastolic volume (LVEDV), stroke volume (SV) and cardiac output (CO) were measured with 2D echocardiography with Simpson's biplane method (Pillip HP sonos 5500) by the same investigator at baseline and at 2.0 h after initiation of saline and GTN infusion. RESULTS: Systolic blood pressure (SBP), diastolic blood pressure (DBP), and left ventricular end-diastolic volume (LVEDV) were decreased, while left ventricular ejection fraction (LVEF) was increased at the end of GTN infusion (p < 0.001, respectively). Saline infusion showed no hemodynamic effects. At the end of GTN infusion, ALDH2*1/*1 homozygous patients showed higher degrees of both the absolute decrease in SBP (DSBP) (p < 0.001) and increase in LVEF (p < 0.001) than carriers of the ALDH2*2 allele. Mean plasma concentration of CGRP was increased after GTN infusion (p < 0.001), but not changed after saline infusion (p > 0.05). Changes in plasma concentration of CGRP correlated positively with the improvement in LVEF (r = 0.400, p = 0.004), while correlated negatively with changes in SBP (r = -0.300, p = 0.036) and LVEDV (r = -0.290, p = 0.043). CONCLUSIONS: ALDH2*2 polymorphism is associated with contributions of CGRP to GTN response in CHF patients.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2012) studied chronic heart failure (n=49). Nitroglycerin (GTN) vs. Saline was evaluated on Hemodynamic changes (SBP, DBP, LVEDV, LVEF) and plasma CGRP (p=<0.001). Nitroglycerin infusion significantly improved hemodynamics and increased plasma CGRP in CHF patients (p<0.001), with ALDH2*1/*1 homozygous patients showing greater responses than ALDH2*2 carriers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: